EvokAI Creative Labs

EvokAI Creative Labs FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of EvokAI Creative Labs (OKAI.V) as of Oct 22, 2026 is 14.83 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 69.47 % — a change of -78.65% (lower).

FCF Conversion

14.83 %

YoY

-78.65%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of EvokAI Creative Labs is 2023 14.83 % . FCF Conversion Rate (FCF/EBITDA) of EvokAI Creative Labs was 2022 69.47 % . It decreases by -78.65% lower compared to the previous year.

The EvokAI Creative Labs FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
88.04 USD
Jan 1, 2021
104.12 USD
Jan 1, 2022
69.47 USD
Jan 1, 2023
14.83 USD
The EvokAI Creative Labs FCF Conversion history
YEARFCF ConversionYoY
14.83 %-78.65%
69.47 %-33.27%
104.12 %+18.27%
88.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EvokAI Creative Labs Stock analysis

What does EvokAI Creative Labs do? EvokAI Creative Labs Inc develops AI algorithms for healthcare, deploying machine learning to search medical data and uncover insights for improved health outcomes. The company offers its AI solutions across the healthcare system, targeting hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations, medical professionals, patients, and healthy individuals. Its divisions include EvokAI Simulators, EvokAI Sensors, EvokAI Neurotrainer, and EvokAI Medical, with EvokAI Simulators combining cognitive neuroscience, virtual reality, and AI to assess cognitive performance and spatial perception. The company generates revenue by providing AI-driven insights and tools to healthcare stakeholders, including pharmaceutical companies and research institutions, for drug development, clinical decisions, and disease prevention. EvokAI Simulators specifically serves medical professionals and patients seeking cognitive assessments through virtual reality and AI integration. EvokAI Medical supports healthcare providers in delivering accurate diagnoses and improving patient experiences. EvokAI Sensors and EvokAI Neurotrainer cater to diverse healthcare segments, from early disease detection to enhancing cognitive training. The company's focus on preventing and early detecting diseases aligns with the needs of aging populations and health-conscious individuals, driving demand for its AI-powered solutions across the healthcare ecosystem. EvokAI Creative Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EvokAI Creative Labs stock

FCF Conversion Rate (FCF/EBITDA) of EvokAI Creative Labs is 14.83 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of EvokAI Creative Labs changed from 69.47 % to 14.83 %, representing a -78.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) EvokAI Creative Labs since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s EvokAI Creative Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — EvokAI Creative Labs

All Key Metrics — EvokAI Creative Labs